This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why you Should Retain Veeva Systems Stock in Your Portfolio Now
by Zacks Equity Research
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
CLPT Stock Gains on FDA Clearance for Navigation Software Version 3.0
by Zacks Equity Research
ClearPoint achieves FDA 510(k) clearance for its Navigation Software Version 3.0, designed to standardize cell and gene therapy delivery in the United States.
Reasons to Retain ABT Stock in Your Portfolio Now
by Zacks Equity Research
Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.
VEEV Stock Falls Despite Tie-Up to Streamline Customers' Operations
by Zacks Equity Research
Veeva Systems aims to simplify master data configuration during LIMS implementation and site deployment and enable companies to advance beyond legacy QC systems.
Expanding EPD Business Supports ABT Stock Amid Macro Issues
by Zacks Equity Research
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
BellRing Brands (BRBR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BD Stock Rises on Biosero Deal for AI-Powered Robotic Cytometry Tech
by Zacks Equity Research
BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MYGN Stock Gains Following the Launch of Know More Sooner
by Zacks Equity Research
Myriad Genetics launches an online prenatal genetic testing resource, the Know More Sooner website, to provide comprehensive information about reproductive and prenatal genetic testing.
TEM Stock Rises on Launch of AI-Powered Health Concierge App
by Zacks Equity Research
Tempus AI announces the launch of olivia, an AI-enabled personal health concierge app designed to revolutionize patient care and engagement nationwide.
Here's Why you Should Add Nevro Stock to Your Portfolio Now
by Zacks Equity Research
NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 preliminary results amid a weak SCS market.
ResMed (RMD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Brainsway Ltd. Sponsored ADR (BWAY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Brainsway (BWAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Tandem Diabetes Gains 45.7% in a Year: What's Driving the Stock?
by Zacks Equity Research
TNDM's shares rise as its expanding product portfolio gains market traction. However, the unfavorable macroeconomic scenario is concerning.
Emerging Market Expansion Supports ZBH Stock Amid Macro Issues
by Zacks Equity Research
Zimmer Biomet is witnessing strong market share gains within reconstructive Knees and Hips in key geographies despite macroeconomic challenges.
Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock
by Zacks Equity Research
Valneva reports positive data from its Phase 3 - VLA1553-321 study of the IXCHIQ vaccine.
Reasons to Retain TNDM Stock in Your Portfolio for Now
by Zacks Equity Research
A robust diabetes market and several strategic developments raise investors' optimism for Tandem Diabetes.
BSX Stock Rises on Positive Data Announcement at the AF Symposium
by Zacks Equity Research
Boston Scientific announces favorable study data for its FARAPULSE PFA system and WATCHMAN FLX device at the AF Symposium 2025.
Strategic Collaborations Aid QGEN Stock Amid Competition
by Zacks Equity Research
QIAGEN invests heavily in research and development to support internal growth, including the menu expansion of its key platforms.
NEOG Stock Gains Following the Launch of Its New MDA2QSAL96 Kit
by Zacks Equity Research
Neogen launches the new Molecular Detection Assay 2 - Quantitative Salmonella (MDA2QSAL96) to deliver consistency and sensitivity with an easy-to-use workflow that saves time and resources.
Align Technology Shares Hurt by Macro Issues, Decline in ASPs
by Zacks Equity Research
ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This resulted in a decline in the company's revenues.
Reasons to Retain Envista Stock in Your Portfolio for Now
by Zacks Equity Research
NVST's strong focus on international market expansion appears promising. Yet, a leveraged balance sheet is worrisome.
HSIC Stock Might Rise Following the Acquisition of Acentus
by Zacks Equity Research
Henry Schein completes the acquisition of Acentus, which expands the former's Home Solution business.
Nevro Stock Falls Despite Q4 Sales Beat on Strong SCS Demand
by Zacks Equity Research
NVRO's preliminary fourth-quarter revenues showcase decline in worldwide and U.S. revenues.
The Zacks Analyst Blog Highlights Vertiv, Goldman Sachs, ResMed, Ralph Lauren and Amazon
by Zacks Equity Research
Vertiv, Goldman Sachs, ResMed, Ralph Lauren and Amazon are included in this Analyst Blog.